Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1)

The summary for the Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1): The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support to complete the Strategic Timing of Antiretroviral Treatment (START) trial. START is a randomized clinical trial to determine if immediate initiation of antiretroviral treatment (ART) in HIV-positive patients is superior in delaying the occurrence of AIDS, non-AIDS events and death.